Intravenous immunoglobulin (IVIg) is obtained from the blood serum and is prepared using 1000 to 15000 donors per batch. It is used in the treatment of clients who are suffering from deficiencies of antibodies and is a preferred treatment. Due to this indication, the blood product is administered in quantities of 200-400 mg per kg of body weight which is considered to be the replacement dose and this is done in intervals of around 3 weeks. Apart from this, high dosage of this blood product which is often taken to be 2 g per kg per month is administered to clients with inflammatory and immune disorders, in the form of an immunomodulatory agent.
Market for intravenous immunoglobulin (IVIg)
The global market for intravenous immunoglobulin is expected to increase at a substantial compound annual growth rate (CAGR) during the forecast period of 2016-2022. The growth in the awareness regarding IVIg treatment, increase in the number of incidents of hemophilia and deficiency of antibodies and technological advancements in these products have been the market driving factors for this. The increased use of these products due to the benefits that are extended by them to the clients has led to the expansion of the market industry for intravenous immunoglobulin.
Further details about intravenous immunoglobulin
Intravenous immunoglobulin comprises of blood products that are sterile in nature and are purified products of IgG. These are obtained from the pooled human plasma and specifically consist of unmodified IgG in which are more than 95%. Intravenous immunoglobulin is applicable in many branches of the medical field which include haematology, dermatology, nephrology, immunology, rheumatology and neurology. This blood product has a significant role in treating neurological problems such as chronic inflammatory demyelinating polyneuropathy (CIDP), dermatomyositis, myasthenia gravis, Guillan-Barre syndrome, stiff person syndrome and multifocal motor neuropathy (MMN). In the branch of haematology, IVIg is applicable in the treatment of red cell aplasia associated with parvovirus B19, post bone marrow transplantation, hypogammaglobulinaemia, immune cytopenias and chronic lymphatic leukemia. In the branches of rheumatology, nephrology and ophthalmology, IVIg is implemented in the treatment of systemic lupus erythematosis (SLE), vasculitis, uveitis and mucous membrane pemphigoid while in dermatology this product is applied most often in treating dermatomyositis, Kawasaki syndrome, blistering diseases and toxic epidermal necrolysis. One of the most significant developments in the recent times regarding intravenous immunoglobulin is the application of formulations based on sorbitol against formulations based on sucrose.
Intravenous immunoglobulin is the result technological developments that have taken place in the medical arena. The implementations of this product in multiple branches and the immense uses have driven the market, hence providing a substantial growth in the recent times.